Galmed Pharmaceuticals (GLMD) Institutional Ownership $1.42 -0.05 (-3.08%) As of 12:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Galmed Pharmaceuticals (NASDAQ:GLMD)CurrentInstitutional OwnershipPercentage76.14%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$81.03KNumber ofInstitutional Sellers(last 12 months)0 Get GLMD Insider Trade Alerts Want to know when executives and insiders are buying or selling Galmed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GLMD Institutional Buying and Selling by Quarter Galmed Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Schonfeld Strategic Advisors LLC25,400$81K0.0%N/A3.969% 5/7/2024CVI Holdings LLC74,665$25K0.0%-72.3%1.479% 8/15/2023BVF Inc. IL89,853$261K0.0%-93.3%5.348% 5/16/2023BVF Inc. IL1,347,755$575K0.0%-22.5%5.348% 7/18/2022 Western Wealth Management LLC59,074$38K0.0%N/A0.235% 2/8/2022Raymond James & Associates203,540$370K0.0%-11.4%0.811% 2/7/2022 Ibex Investors LLC874,144$1.59M0.5%-26.7%3.485% 11/16/2021Squarepoint Ops LLC25,404$71K0.0%-22.2%0.101% 11/16/2021Toroso Investments LLC24,657$69K0.0%N/A0.098% 11/5/2021 Ibex Investors LLC1,193,100$3.33M0.7%-2.3%4.756% 11/2/2021Raymond James Financial Services Advisors Inc.21,304$59K0.0%+27.2%0.085% 11/2/2021Raymond James & Associates229,640$641K0.0%+10.5%0.915% 8/16/2021Squarepoint Ops LLC32,634$99K0.0%-40.5%0.130% 8/16/2021Nantahala Capital Management LLC944,631$2.87M0.1%-22.2%3.766% 8/16/2021 Ibex Investors LLC1,220,794$3.71M1.3%-19.9%4.867% 8/5/2021 Ibex Investors LLC1,220,794$3.71M1.3%-19.9%4.868% 7/31/2021 Brave Asset Management Inc.11,470$35K0.0%N/A0.046% 5/19/2021Squarepoint Ops LLC54,884$188K0.0%+161.2%0.219% 5/17/2021Goldman Sachs Group Inc.26,419$91K0.0%N/A0.105% (Data available from 1/1/2016 forward) GLMD Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GLMD shares? During the previous two years, the following institutional investors and hedge funds held shares of Galmed Pharmaceuticals shares: BVF Inc. IL ($261K), and Schonfeld Strategic Advisors LLC ($81K), CVI Holdings LLC ($25K).Learn more on Galmed Pharmaceuticals' institutional investors. What percentage of Galmed Pharmaceuticals' stock is owned by institutional investors? 76.14% of Galmed Pharmaceuticals' stock is owned by institutional investors. Learn more on GLMD's institutional investor holdings. Which institutional investors have been buying Galmed Pharmaceuticals' stock? The following institutional investors have purchased Galmed Pharmaceuticals' stock in the last 24 months: Schonfeld Strategic Advisors LLC ($25.40K). How much institutional buying is happening at Galmed Pharmaceuticals? Institutional investors have bought a total of 25,400 shares in the last 24 months. This purchase volume represents approximately $81.03K in transactions. Related Companies BFRI Institutional Ownership SNGX Institutional Ownership APRE Institutional Ownership DWTX Institutional Ownership RNAZ Institutional Ownership ADXN Institutional Ownership XFOR Institutional Ownership CELZ Institutional Ownership SNPX Institutional Ownership CLRB Institutional Ownership This page (NASDAQ:GLMD) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTesla is in troubleThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access